|
Market Closed -
OTC Markets
22:17:26 04/06/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.0452 USD | -1.31% |
|
+13.00% | +126.00% |
| Market Cap | 5.07M 3.65M 3.15M 2.96M 2.7M 349M 5.15M 34.73M 13.58M 175M 13.71M 13.41M 581M | P/E 2024 |
-6.82x | P/E 2025 | -2.84x |
|---|---|---|---|---|---|
| Enterprise Value | 9.47M 6.82M 5.89M 5.54M 5.03M 652M 9.62M 64.87M 25.36M 327M 25.61M 25.05M 1.09B | EV / Sales 2024 |
1.15x | EV / Sales 2025 | 0.85x |
| Free-Float |
89.84% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -1.31% | ||
| 1 week | +13.00% | ||
| Current month | -8.50% | ||
| 1 month | +29.89% | ||
| 3 months | +45.81% | ||
| 6 months | -30.46% | ||
| Current year | +126.00% |
| 1 month | 0.01 | 0.05 | |
| Current year | 0 | 0.07 | |
| 1 year | 0 | 0.07 | |
| 3 years | 0 | 0.16 | |
| 5 years | 0 | 0.4 | |
| 10 years | 0 | 2.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Taz Turner
CEO | Chief Executive Officer | - | 22/09/2017 |
Ashish Kapoor
DFI | Director of Finance/CFO | 48 | 10/03/2015 |
Graeme Hawkins
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Taz Turner
CHM | Chairman | - | 17/05/2018 |
Benjamin Higham
BRD | Director/Board Member | - | 08/04/2020 |
Jakob Ripshtein
BRD | Director/Board Member | 60 | 08/04/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 17/12/23 | Buy | Director | 30,000 | 0.0274% | ||
| 17/12/23 | Buy | Director | 500 | 0.0005% | ||
| 17/12/23 | Buy | Director | 500 | 0.0005% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.31% | +13.00% | -24.29% | -66.52% | 4.39M | ||
| -2.24% | +4.69% | -5.72% | +11.79% | 1.58B | ||
| -5.62% | -7.11% | +31.24% | +140.66% | 844M | ||
| +0.62% | +2.19% | -11.41% | +91.76% | 206M | ||
| 0.00% | +10.96% | -31.93% | -64.63% | 180M | ||
| -0.65% | +8.93% | -21.82% | +17.66% | 91.86M | ||
| -0.69% | +2.51% | +41.58% | -47.23% | 82.58M | ||
| Average | -1.41% | +3.47% | -3.19% | +11.93% | 427.53M | |
| Weighted average by Cap. | -2.77% | +2.95% | +3.51% | +47.48% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 13.8M 9.94M 8.59M 8.07M 7.34M 951M 14.02M 94.55M 36.97M 476M 37.33M 36.52M 1.58B | 14.25M 10.27M 8.87M 8.33M 7.58M 982M 14.48M 97.65M 38.18M 492M 38.55M 37.71M 1.63B |
| Net income | -1.49M -1.08M -929K -873K -794K -103M -1.52M -10.23M -4M -51.5M -4.04M -3.95M -171M | -2.69M -1.94M -1.67M -1.57M -1.43M -185M -2.74M -18.44M -7.21M -92.84M -7.28M -7.12M -309M |
| Net Debt | 5.66M 4.08M 3.52M 3.31M 3.01M 390M 5.75M 38.77M 15.16M 195M 15.31M 14.98M 649M | 4.4M 3.17M 2.74M 2.57M 2.34M 303M 4.47M 30.14M 11.78M 152M 11.9M 11.64M 504M |
Employees
-
Sector
Drug Retailers
- Stock Market
- Stocks
- LVRLF Stock
Select your edition
All financial news and data tailored to specific country editions
















